Sales Compensation, Quota Capacity & Commission PlansPlaybook3 min readUpdated September 2026

Why a SaaS Commission Plan Doesn't Transfer to Fintech or Health Tech

A commission plan that attracts strong reps at a horizontal SaaS company can look unremarkable, or even weak, to an experienced fintech or health tech seller, and the reverse is just as true. The differences aren't arbitrary; they follow from how each vertical's sales cycle, deal complexity, and regulatory review actually work.

Here's a comparison of how the three tend to differ and what that means for designing a plan.

Vendors Covered in this Article

Disclosure: We may earn a commission if you buy through some links on this page. It doesn't change what we recommend.

Horizontal SaaS: Shorter Cycles, More Variable Weight

A typical horizontal SaaS motion, especially in the mid-market or smaller enterprise segment, has a comparatively short sales cycle and a rep who largely controls the outcome through their own effort. This supports a pay mix that leans more heavily toward variable compensation, since reps see the payoff of extra effort within a reasonably short window, and the company can afford to let strong performers earn well above target without an unusually long wait.

Fintech: Longer Cycles, More Stakeholders, More Base

Fintech sales, particularly anything touching payments, lending, or banking infrastructure, tends to involve a longer cycle with compliance and risk stakeholders who weren't part of a comparable SaaS deal's approval chain. A rep's individual influence over the timeline is correspondingly lower, since much of the delay comes from the buyer's internal review process rather than anything the rep can accelerate through effort alone. This typically supports a more base-heavy pay mix and, often, a longer window before quota relief or plan changes apply, reflecting the extended cycle.

Experienced fintech sellers generally expect this tradeoff and evaluate an offer accordingly, weighing a steadier income against a longer wait for any single deal's variable payout. A plan that ignores this expectation and copies a fast-cycle structure tends to read, to that candidate pool, as a company that doesn't understand its own sales motion yet.

Health Tech: Regulatory Review Adds Real Cycle Length

Health tech sales, especially anything touching clinical workflows or patient data, adds regulatory and compliance review on top of the buyer's normal procurement process, often involving security, legal, and clinical stakeholders who each need separate sign-off. Commission plans in this vertical usually build in an even longer runway before a deal is expected to close, and quota targets need to reflect that reality rather than being copied from a shorter-cycle SaaS benchmark.

What Stays Consistent Across All Three

Despite the differences in cycle length and pay mix, a few principles hold regardless of vertical: commission should still be tied to a clear, auditable deal record; accelerators should still reward genuine outperformance rather than routine attainment; and the plan should still be explainable to a new rep in plain language without needing a finance background to understand their own paycheck.

These constants matter because they're what a rep evaluating an offer actually compares across companies, even within the same vertical. Two fintech companies can both have appropriately long cycles and base-heavy mixes, yet one plan will still feel clearer and more trustworthy than the other based purely on how well it follows these basics.

Keep these principles fixed in every vertical:

  • Tie commission to a clear, auditable deal record, so any payout can be traced back to a specific deal.
  • Use accelerators to reward genuine outperformance rather than routine attainment.
  • Write the plan so a new rep can understand it in plain language without a finance background.
  • Adjust pay mix and cycle assumptions for each vertical instead of copying a plan from a shorter-cycle segment.

The Risk of Copying a Plan From the Wrong Vertical

A company moving from a shorter-cycle vertical into a longer-cycle one, for instance a SaaS company expanding into a regulated fintech or health tech segment, often makes the mistake of applying its existing plan unchanged. Reps in the new segment then face months of little to no commission before their first deal clears an unfamiliar approval gauntlet, which reads as broken income, not just a longer wait, and tends to drive early attrition on exactly the deals the company most needs experienced reps to stick around for.

Benchmarking Against the Right Comparison Set

When benchmarking your own plan, compare against companies actually selling into the same vertical and buyer type, not against a generic industry average that blends fast-cycle transactional sales with slow-cycle regulated sales. Pipedrive and Rippling both help track your own internal cycle-length and attainment data by segment, which is the more reliable input for calibrating a plan than an external benchmark that doesn't distinguish between verticals with fundamentally different buying processes.

Executive Capability Standard

What Good Looks Like

A vertical-appropriate commission plan is calibrated to that vertical's actual sales cycle length and the rep's real influence over the timeline, benchmarked against comparable companies in the same vertical rather than a generic cross-industry average.

Building The Capability (5-Stage Skill Ladder)

1. Learn:Compare your actual cycle length and rep attainment by vertical, if you sell into more than one, before assuming one plan fits both.
2. Do Manually:Talk to a few experienced reps who've sold in the relevant vertical elsewhere about what pay mix and cycle expectations felt normal to them.
3. Delegate:Have RevOps maintain segment-specific cycle-length and attainment data so plan calibration is based on real internal numbers.
4. Automate:Track cycle length and attainment by vertical in Pipedrive, with payout differences applied correctly through Rippling.
5. Buy:Bring in a compensation benchmarking service with vertical-specific data if you're entering a new regulated vertical for the first time.

How to Get Started

Disclosure: We may earn a commission if you buy through some links on this page. It doesn't change what we recommend.

Frequently Asked Questions

Should a company selling into multiple verticals run separate comp plans for each?

Often yes, once the cycle-length difference between verticals becomes significant. Running one plan calibrated to the shortest cycle penalizes reps in the longer-cycle vertical, while calibrating to the longest cycle overpays reps closing faster, simpler deals.

How do we know if our fintech or health tech cycle is genuinely longer, or if it's a process problem?

Compare your cycle length against companies selling comparable products into the same buyer type and regulatory environment. If yours is significantly longer than that comparison set, the gap may point to an internal process issue worth fixing rather than an inherent feature of the vertical.

Does a longer sales cycle always mean a base-heavy pay mix is the right answer?

It's the more common pattern, but not automatic. If a rep still has strong individual influence over accelerating a long cycle, through relationship management or navigating internal stakeholders skillfully, a more balanced mix can still make sense even with an extended timeline.

About the numbers

This guide doesn't quote a sourced benchmark. Figures in it are estimates or general guidance, so check them against your own numbers.

Related Guides